Ameliorative effect and mechanism of Yi‐Suan‐Cha against hyperuricemia in rats
Authors:
Open Access
- 12 July 2021
- journal article
- research article
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 35 (8) , e23859
Abstract
Background: This study aimed to evaluate the urate‐lowering effects of Yi‐Suan‐Cha and explore its underlying mechanisms in experimental hyperuricemia induced in rats.Methods: Forty‐eight male SD rats were randomly allocated into normal control, model, allopurinol, benzbromarone, low‐dose Yi‐Suan‐Cha (0.2 g/ml), and high‐dose Yi‐Suan‐Cha (0.4 g/ml) groups (n = 8 rats per group). Rat models of hyperuricemia were established through intragastric administration of adenine 25 mg/kg + potassium oxalate 300 mg/kg for 3 weeks. After the last administration, serum uric acid, creatinine, and urea nitrogen levels were measured. Renal histopathology was observed by hematoxylin‐eosin staining. Xanthine oxidase level in serum and liver homogenates was measured by ELISA. The protein and mRNA expression of URAT1, ABCG2, OAT1, and GLUT9 in the kidney was detected by Western blotting and RT‐PCR, respectively.Results: The serum uric acid levels were significantly lowered in all medication groups than in the model group. The benzbromarone and both Yi‐Suan‐Cha groups showed clear kidney structures with no obvious abnormalities. Compared with the normal control group, the model group showed increased URAT1/GLUT9 protein expression and decreased ABCG2/OAT1 protein expression. Compared with the model group, both Yi‐Suan‐Cha groups showed decreased URAT1/GLUT9 protein expression and increased ABCG2/OAT1 protein expression. Compared with that in the normal control group, URAT1/GLUT9 mRNA expression increased in the model group. Compared with the model group, the low‐dose and high‐dose Yi‐Suan‐Cha groups showed decreased URAT1/GLUT9 mRNA expression and increased ABCG2/OAT1 mRNA expression.Conclusion: Yi‐Suan‐Cha may lower uric acid level by downregulating URAT1/GLUT9 expression and upregulating ABCG2/OAT1 expression.Keywords
Funding Information
- Natural Science Foundation of Guangxi Province (2017JJA10152)
This publication has 32 references indexed in Scilit:
- Renal Transport of Uric Acid: Evolving Concepts and UncertaintiesAdvances in Chronic Kidney Disease, 2012
- Advanced Kidney Failure and HyperuricemiaAdvances in Chronic Kidney Disease, 2012
- Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2PLOS ONE, 2012
- Effect of the Metabolic Syndrome and Hyperuricemia on Outcome in Patients With Coronary Artery Disease (from the Bezafibrate Infarction Prevention Study)The American Journal of Cardiology, 2010
- Human Sodium Phosphate Transporter 4 (hNPT4/SLC17A3) as a Common Renal Secretory Pathway for Drugs and UrateJournal of Biological Chemistry, 2010
- What lies behind serum urate concentration? Insights from genetic and genomic studiesGenome Medicine, 2009
- Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and IsraelJournal of the American Academy of Dermatology, 2008
- Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissuesNature Clinical Practice Nephrology, 2007
- Clinical and Molecular Analysis of Patients with Renal Hypouricemia in Japan-Influence of URAT1 Gene on Urinary Urate ExcretionJournal of the American Society of Nephrology, 2004
- Molecular identification of a renal urate–anion exchanger that regulates blood urate levelsNature, 2002